SCHEMBL1015149

SCHEMBL1015149

O=C(Nc1cccc(-c2ccoc2)c1)C(=O)Nc1ccc(Cl)cc1C(=O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SERPINE1 P05121 8/20 1.00
CNR1 P21554 1/20 0.61
GRIK1 P39086 3/20 0.51
KDM4E B2RXH2 2/20 0.46
HSD17B10 Q99714 1/20 0.46
MEN1 O00255 1/20 0.46
ALDH1A1 P00352 1/20 0.46
KMT2A Q03164 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
MPO P05164 1/20 0.46
AKR1C4 P17516 1/20 0.46
AKR1C3 P42330 1/20 0.46
AKR1C2 P52895 1/20 0.46
AKR1C1 Q04828 1/20 0.46
PTPN1 P18031 1/20 0.44
FABP3 P05413 1/20 0.44
FABP4 P15090 1/20 0.44
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29492571 1.00 SERPINE1 (1.00) SERPINE1CNR1GRIK1KDM4EHSD17B10
SCHEMBL1012706 0.89 SERPINE1 (0.80) SERPINE1CNR1GRIK1KDM4EHSD17B10
SCHEMBL1015090 0.88 SERPINE1 (0.79) SERPINE1CNR1GRIK1MEN1ALDH1A1
SCHEMBL1014817 0.86 SERPINE1 (0.76) SERPINE1CNR1GRIK1KDM4EHSD17B10
SCHEMBL29492572 0.86 SERPINE1 (0.77) SERPINE1CNR1GRIK1KDM4EHSD17B10
SCHEMBL1016107 0.86 SERPINE1 (0.77) SERPINE1CNR1GRIK1KDM4EHSD17B10
SCHEMBL22468222 0.85 SERPINE1 (0.75) SERPINE1CNR1GRIK1KDM4EHSD17B10
SCHEMBL1015517 0.84 SERPINE1 (1.00) SERPINE1CNR1KDM4EHSD17B10AKR1C4
SCHEMBL420979 0.83 SERPINE1 (1.00) SERPINE1AKR1C4AKR1C3AKR1C2AKR1C1
SCHEMBL418577 0.81 SERPINE1 (0.73) SERPINE1CNR1KDM4EHSD17B10ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113056268-A Plasminogen activator inhibitor 1(PAI-1) inhibitors and uses thereof 艾里奥治疗公司 2021-06-29 CN claimed
CN-113056269-A Use of plasminogen activator inhibitor 1(PAI-1) inhibitors 艾里奥治疗公司 2021-06-29 CN claimed
EP-2990057-B1 PAI-1 INHIBITOR FOR USE IN ENHANCING THE ANTITUMOR EFFECT OF AN ANTITUMOR AGENT IN A PATIENT RENASCIENCE CO LTD (JP) 2019-03-20 EP claimed
US-10092537-B2 Use for PAI-1 inhibitor RENASCIENCE CO., LTD. (JP) 2018-10-09 US claimed
US-20160158188-A1 NOVEL USE FOR PAI-1 INHIBITOR RENASCIENCE CO., LTD. (JP) 2016-06-09 US claimed
EP-2990057-A1 NOVEL USE FOR PAI-1 INHIBITOR Renascience Co., Ltd. (JP) 2016-03-02 EP claimed
US-8415479-B2 Inhibitor of plasminogen activator inhibitor-1 RENASCIENCE CO., LTD. (JP) 2013-04-09 US claimed
US-20110112140-A1 INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 RENASCIENCE CO., LTD. (JP) 2011-05-12 US claimed
EP-2272822-A1 INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 Renascience CO., LTD. (JP) 2011-01-12 EP claimed
CN-113056269-A Use of plasminogen activator inhibitor 1(PAI-1) inhibitors 艾里奥治疗公司 2021-06-29 CN disclosed
CN-113056268-A Plasminogen activator inhibitor 1(PAI-1) inhibitors and uses thereof 艾里奥治疗公司 2021-06-29 CN disclosed
EP-2990057-B1 PAI-1 INHIBITOR FOR USE IN ENHANCING THE ANTITUMOR EFFECT OF AN ANTITUMOR AGENT IN A PATIENT RENASCIENCE CO LTD (JP) 2019-03-20 EP disclosed
US-10092537-B2 Use for PAI-1 inhibitor RENASCIENCE CO., LTD. (JP) 2018-10-09 US disclosed
US-20160158188-A1 NOVEL USE FOR PAI-1 INHIBITOR RENASCIENCE CO., LTD. (JP) 2016-06-09 US disclosed
EP-2990057-A1 NOVEL USE FOR PAI-1 INHIBITOR Renascience Co., Ltd. (JP) 2016-03-02 EP disclosed
US-8415479-B2 Inhibitor of plasminogen activator inhibitor-1 RENASCIENCE CO., LTD. (JP) 2013-04-09 US disclosed
US-20110112140-A1 INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 RENASCIENCE CO., LTD. (JP) 2011-05-12 US disclosed
EP-2272822-A1 INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 Renascience CO., LTD. (JP) 2011-01-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110112140-A1 INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 SERPINE1, SERPINB1, SERPINC1 SERPINE1 1/4885CNR1 3950/4885GRIK1 3288/4885
US-20160158188-A1 NOVEL USE FOR PAI-1 INHIBITOR SERPINE1, SERPINC1, SERPINB1 SERPINE1 1/4885CNR1 4368/4885GRIK1 3308/4885
US-10092537-B2 Use for PAI-1 inhibitor SERPINE1, SERPINC1, SERPINB1 SERPINE1 1/4885CNR1 4387/4885GRIK1 3254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.